Capricor Therapeutics (CAPR) AI Stock Analysis

• Market Cap: $429.36M
• Dividend Yield: N/A
• Average Volume (3M): 1.62M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.69
• Revenue Growth: -11.55%
• EPS Growth: -37.48%
• Country: US
• Employees: 160
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -1.20
• Shares Outstanding: 45,676,888
• 10 Day Avg. Volume: 1,645,180
• 30 Day Avg. Volume: 1,618,592
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 25.17
• Price to Cash Flow (P/CF): -12.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $43.60
• Price Target Upside: 363.83% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Capricor Therapeutics shows promise with significant progress toward FDA approval and a solid financial runway. However, persistent financial challenges, including profitability and cash flow issues, coupled with weak technical indicators and valuation concerns, weigh heavily on the stock's overall score. The positive sentiment from the earnings call provides some optimism, but operational inefficiencies and increased net losses remain key risks.

Positive Factors

Financial Performance

Capricor announced financial results that exceeded estimates with a lower-than-expected loss, ending the quarter with $151.5 million in cash.

Partnership Expansion

Partnership with Nippon Shinyaku was expanded to include the EU, with combined milestones totaling ~$1.5B, including an $80M milestone for US approval.

Regulatory Progress

The FDA accepted deramiocel's BLA for DMD cardiomyopathy and granted it Priority Review, which is a significant step forward for Capricor.

Negative Factors

Manufacturing Challenges

Capricor is expanding its manufacturing capacity to produce deramiocel for approximately 2,000-3,000 patients, with a new facility expected to be operational by mid-2026.

Regulatory Risks

Capricor plans to file a rolling BLA seeking full approval and a broader label for deramiocel in the treatment of DMD-cardiomyopathy, which may face regulatory hurdles.

Capricor Therapeutics Business Overview & Revenue Model

Company Description

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

How the Company Makes Money

Capricor Therapeutics primarily makes money through the development and commercialization of its therapeutic candidates. The company generates revenue through strategic partnerships, licensing agreements, and research collaborations with other biotech and pharmaceutical companies. These partnerships often include upfront payments, milestone payments, and royalties on sales of any successfully developed therapies. Additionally, the company may receive funding through grants and government contracts to support its research and development efforts. Capricor's key revenue streams are closely linked to the progress and commercialization of its clinical-stage products, such as CAP-1002, which targets Duchenne muscular dystrophy and other cardiac-related conditions.

Capricor Therapeutics Financial Statement Overview

Summary

Capricor Therapeutics exhibits significant financial challenges typical in biotech, with high R&D costs and negative profitability indicators. Despite strong equity and no debt, persistent losses and cash flow issues are concerning.

Income Statement

Capricor Therapeutics has shown significant revenue volatility over the years, with a notable increase in revenue in 2023 compared to previous years, but still operates at a net loss. The gross profit margin is consistently negative, and the EBIT and EBITDA margins are also negative, indicating the company is struggling with profitability. Revenue growth is present but overshadowed by operational inefficiencies and high expenses.

Balance Sheet

The company has a strong equity position with a positive stockholders' equity, and the absence of total debt in the latest year indicates reduced leverage risk. However, the negative total liabilities figure in 2024 raises concerns about data accuracy or financial reporting issues. The equity ratio is favorable given the high equity levels in relation to assets.

Cash Flow

Capricor Therapeutics has experienced fluctuating cash flow from operations, with periods of negative free cash flow, indicating challenges in generating sustainable cash from operations. The free cash flow growth rate is negative, and the operating cash flow to net income ratio is not calculable, highlighting ongoing cash management issues.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
22.27M	25.18M	2.55M	244.90K	310.25K
	Gross Profit
-27.70M	24.11M	1.85M	-799.00	-8.15M
	EBIT
-42.56M	-24.08M	-29.70M	-20.94M	-13.69M
	EBITDA
-41.17M	-23.01M	-29.16M	-20.69M	-13.55M
	Net Income Common Stockholders
-40.47M	-22.29M	―	-19.41M	-13.48M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
85.03M	39.49M	41.42M	34.89M	32.67M
	Total Assets
0.00	58.73M	50.09M	41.33M	34.62M
	Total Debt
0.00	2.24M	2.56M	2.87M	318.16K
	Net Debt
0.00	-12.46M	-7.04M	-32.01M	-32.35M
	Total Liabilities
3.99B	36.13M	38.31M	9.96M	6.42M
	Stockholders Equity
68.26M	22.60M	11.79M	31.37M	28.20M
Cash Flow		Free Cash Flow
0.00	-27.64M	1.56M	-18.01M	-10.60M
	Operating Cash Flow
0.00	-25.60M	4.92M	-16.81M	-10.05M
	Investing Cash Flow
0.00	5.11M	-35.07M	-1.20M	5.44M
	Financing Cash Flow
0.00	25.58M	4.87M	20.23M	33.38M

Capricor Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAPR, the sentiment is Negative. The current price of 9.4 is below the 20-day moving average (MA) of 10.72, below the 50-day MA of 12.71, and below the 200-day MA of 11.89, indicating a bearish trend. The MACD of -1.07 indicates Negative momentum. The RSI at 42.25 is Neutral, neither overbought nor oversold. The STOCH value of 74.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CAPR.

Capricor Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAPR	49 Neutral	$429.36M	―	-48.16%	―	-11.55%	-37.48%
AKBA	49 Neutral	$478.05M	―	91.25%	―	-17.75%	-19.17%
Sector *	48 Neutral	$6.46B	1.17	-48.25%	2.67%	19.50%	0.61%
KROS	46 Neutral	$516.76M	―	-41.46%	―	2250.99%	3.52%
TYRA	42 Neutral	$447.55M	―	-31.60%	―	―	6.72%
TBPH	41 Neutral	$431.88M	―	-29.04%	―	12.12%	-19.00%
MNMD	27 Underperform	$418.29M	―	-68.01%	―	―	26.24%

Capricor Therapeutics Corporate Events

Capricor Therapeutics’ Deramiocel Receives FDA Priority Review

On March 4, 2025, Capricor Therapeutics announced that the FDA has accepted its Biologics License Application for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy cardiomyopathy, and granted it Priority Review with a target action date of August 31, 2025. If approved, deramiocel would be the first therapy for this condition, potentially offering a new treatment landscape for patients and stakeholders in the DMD community.